Results 101 to 110 of about 82,538 (246)

The effect of erythropoietin on normal and neoplastic cells

open access: yes, 2012
Steve Elliott, Angus M SinclairOncology Research, Amgen, Thousand Oaks, CA, USAAbstract: Erythropoietin (Epo) is an essential hormone that binds and activates the Epo receptor (EpoR) resident on the surface of erythroid progenitor cells, thereby ...
Sinclair AM, Elliott S
core  

Antierythropoietin Antibodies in Hemodialysis Patients Treated with Recombinant Erythropoietin

open access: yes, 2014
OBJECTIVE: Erythropoietin resistance is a serious problem in patients treated with recombinant erythropoietin.
Ozturk, Savaş   +13 more
core   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Erythropoietin pathophysiology and erythropoietin deficiency anemia

open access: yes, 2004
Review aerticle on erythropoietin pathophysiology and erythropoietin deficiency ...
CAZZOLA, MARIO
core  

Kidney Disease: A Multiorgan Perspective

open access: yes
Organ Medicine, EarlyView.
Muhammad Nauman Hashmi
wiley   +1 more source

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Serum Erythropoietin level in children with different degrees of chronic renal failure

open access: yesMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2000
Objective: Kidneys are major sites of erythropoietin production and in chronic renal failure (CRF), erythropoietin production decreases and leads to anemia. This study was done in children with different degrees of CRF and with primary disease of tubules
Gh Al-Hosseini Hashemi   +2 more
doaj  

Erythropoietin in patients with type 1 diabetes (review) [PDF]

open access: yesСаратовский научно-медицинский журнал, 2012
The article analyzes the literature on the issue of regulation of erythropoietin in patients with type 1 diabetes. The connection between the secretion of erythropoietin disturbance with the development and progression of diabetes complications has been ...
Khantakova Е.А., Khamnueva L.Yu.
doaj  

Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams   +3 more
wiley   +1 more source

Optimising Haematopoietic Stem Cell Transplantation: Enhancing Myeloablation Sensitivity and Alleviating Anaemia Using Roxadustat (FG‐4592)

open access: yesCell Proliferation, EarlyView.
The use of FG‐4592 in the process of myeloablation can promote haematopoietic cell apoptosis for more effective myeloablation, maintain the number of RBC and may create a pluripotent microenvironment suitable for donor cells, so as to enable more effective haematopoietic reconstruction of donor cells in vivo.
Guanheng Yang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy